BIOCLARMA SRL of Torino at MEDICA 2018 in Düsseldorf -- COMPAMED Trade Fair
Manufacturers

BIOCLARMA SRL

Via Nizza, 52, 10126 Torino
Italy
Telephone +39 011 6706446
Fax +39 011 6708416
info@bioclarma.com

This company is co-exhibitor of
CEIPIEMONTE S.C.p.A. / PIEMONTE AGENCY

Hall map

MEDICA 2018 hall map (Hall 16): stand A67

Fairground map

MEDICA 2018 fairground map: Hall 16

Our range of products

Product categories

  • 03  Diagnostics
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.04  Other molecular diagnostics testing

Our products

Product category: Other molecular diagnostics testing

Gene Specific FISH Probes

Gene Specific probes are designed to hybridize to a precise gene location. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads. Gene specific probes are available in both single and dual colors. ASR and CE marked gene specific probes are available.

Clinical Probes

More Less

Product category: Other molecular diagnostics testing

PNAClamp™ Mutation Detection Kit EGFR (ver.2)

Lung cancer is categorized into two types; non-small cell lung cancer (NSCLC) with the 80~85% frequency and small cell lung cancer with the 15~20% frequency. Epidermal growth factor receptor (EGFR) is expressed on the surface of epidermal cells and has the tyrosine kinase activity. Overexpression of EGFR is found only in NSCLC and may lead to signal transduction system in cells by causing cell proliferation, tumor-induced neoangiogenesis (formation of new blood vessels) and transition induction. The EGFR tyrosine kinase inhibitor (TKI), gefinitib (Iressa, AstraZenca) or erlotinib (Tarceba, Roche), is effective to inhibit the growth of cancer cells and leads to death of cancer cells and suppression of new blood vessels in lung cancer tissue. Especially, some specific mutations in the ATP-binding domain of EGFR gene have strong positive correlation with the response rate of EGFR-TKIs. Furthermore, NSCLC patients with the EGFR mutations are reported to be more effective to EGFR-TKI and show prolonged survival rate of patients with lung cancer. Therefore, detection of the EGFR mutation is becoming an important prognostic biomarker for drug response, and efficient detection of the EGFR mutation is expected to be highly helpful for increase of survival rate of patients with lung cancer in targeted therapy.

More Less

About us

Company details

Bioclarma is a company established in 2007 that provides Products and Services for in vitro testing of biological samples through the use of innovative analytical technologies.

Our molecular diagnostic products, developed with the most advanced technology solutions, are a complete solution for public and private analysis laboratories that carry out genetic and oncological activities.

The Bioclarma Analytical Service is available primarily for research centers, where our company is able to provide accurate and documented analytical responses as well as highly qualified service in the interpretation of the data provided.

Bioclarma laboratories provide analysis service based on the use of Luminex® technology (a liquid phase array system) that allows, by reading fluorescent microspheres, multiple and simultaneous analysis of a large number of analytes on small sample quantities.

The opportunity offered by Bioclarma is to make available to any research laboratory the possibility of simultaneous "multiplex" analysis of cytokines, chemokines, growth factors, signal transduction molecules, DNA / RNA mutations and polymorphisms.

Our company also develops qualitative and / or quantitative assays using the Digital Droplet PCR (ddPCR) and Real Time PCR methods for the development and validation of on-demand analytical tests, with the possibility of implementing the assays on different platforms for amplification and automatic extraction.

Thanks to the experience developed by our research engineers, we can also develop assays based on methods such as in situ fluorescence hybridization (FISH), customized ELISA assays, and various types of immunoenzymatic assays.

More Less